Thomas Shrader
Stock Analyst at BTIG
(2.98)
# 1,673
Out of 5,045 analysts
58
Total ratings
47.06%
Success rate
0.59%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings | Maintains: Buy | $48 → $23 | $9.63 | +138.84% | 2 | Oct 22, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $1.52 | - | 4 | Oct 22, 2025 | |
| GANX Gain Therapeutics | Reiterates: Buy | $9 | $1.76 | +411.36% | 4 | Oct 15, 2025 | |
| CMPS COMPASS Pathways | Maintains: Buy | $7 → $14 | $6.30 | +122.22% | 1 | Oct 13, 2025 | |
| STOK Stoke Therapeutics | Maintains: Buy | $28 → $39 | $31.70 | +23.03% | 1 | Oct 13, 2025 | |
| COYA Coya Therapeutics | Reiterates: Buy | $15 | $6.12 | +145.10% | 2 | Sep 30, 2025 | |
| HROW Harrow | Reiterates: Buy | $63 | $37.56 | +67.73% | 3 | Sep 29, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Buy | $72 | $54.47 | +32.18% | 1 | Sep 8, 2025 | |
| ACIU AC Immune | Reiterates: Buy | $8 | $3.38 | +136.69% | 2 | Sep 8, 2025 | |
| BHVN Biohaven | Maintains: Buy | $59 → $60 | $17.39 | +245.03% | 3 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.73 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $9 | $5.03 | +78.93% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.37 | +191.97% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $44.75 | +257.54% | 4 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.17 | - | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.42 | +1,815.25% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $8.61 | +596.86% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $2.93 | +138.91% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.69 | +1,796.70% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $22 | $2.22 | +890.99% | 2 | Oct 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.64 | +3,009.76% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.15 | +210.68% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.52 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $16.38 | - | 2 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $58 | $14.84 | +290.84% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.24 | +141.94% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $149.61 | +131.27% | 3 | Feb 21, 2019 |
Arcturus Therapeutics Holdings
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $9.63
Upside: +138.84%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.52
Upside: -
Gain Therapeutics
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $1.76
Upside: +411.36%
COMPASS Pathways
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $6.30
Upside: +122.22%
Stoke Therapeutics
Oct 13, 2025
Maintains: Buy
Price Target: $28 → $39
Current: $31.70
Upside: +23.03%
Coya Therapeutics
Sep 30, 2025
Reiterates: Buy
Price Target: $15
Current: $6.12
Upside: +145.10%
Harrow
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $37.56
Upside: +67.73%
Bright Minds Biosciences
Sep 8, 2025
Initiates: Buy
Price Target: $72
Current: $54.47
Upside: +32.18%
AC Immune
Sep 8, 2025
Reiterates: Buy
Price Target: $8
Current: $3.38
Upside: +136.69%
Biohaven
Aug 19, 2025
Maintains: Buy
Price Target: $59 → $60
Current: $17.39
Upside: +245.03%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.73
Upside: -
Apr 7, 2025
Maintains: Buy
Price Target: $11 → $9
Current: $5.03
Upside: +78.93%
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.37
Upside: +191.97%
Feb 24, 2025
Reiterates: Buy
Price Target: $160
Current: $44.75
Upside: +257.54%
Sep 4, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.17
Upside: -
Oct 3, 2023
Initiates: Buy
Price Target: $8
Current: $0.42
Upside: +1,815.25%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $8.61
Upside: +596.86%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $2.93
Upside: +138.91%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.69
Upside: +1,796.70%
Oct 5, 2022
Maintains: Buy
Price Target: $15 → $22
Current: $2.22
Upside: +890.99%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.64
Upside: +3,009.76%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $5.15
Upside: +210.68%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $4.52
Upside: -
Oct 16, 2020
Downgrades: Neutral
Price Target: n/a
Current: $16.38
Upside: -
Sep 15, 2020
Maintains: Buy
Price Target: $51 → $58
Current: $14.84
Upside: +290.84%
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.24
Upside: +141.94%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $149.61
Upside: +131.27%